menu

Potassium Management Made Easy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Potassium Management Made Easy

close
0.25 credits
15 minutes
Potassium Management Made Easy
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    The most common risk factors for hyperkalemia are reduced kidney function and treatment with renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. With evidence showing the increased risk of morbidity and mortality associated with hyperkalemia caused by stopping RAASi therapy, how can we best manage potassium abnormalities and protect our patients through optimized RAASi therapy?

    This panel discussion featuring Drs. George Bakris, Matthew Weir, and Faiez Zannad will highlight the latest tools for treating hyperkalemia as well as practice tips for its continued management while titrating RAASi therapy to the most effective levels. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    George Bakris, MD
    Professor of Medicine
    Director, AHA Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, IL 

    Consulting Fees: Alnylam, Ionis, Merck, Relypsa
    Principal Investigator/Steering Committee: Bayer, Novo Nordisk, Vascular Dynamics 

    Faculty:
    Matthew R. Weir, MD
    Division Head, Nephrology
    University of Maryland
    School of Medicine
    Baltimore, MD 

    Consulting Fees: AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Relypsa, Vifor Pharma

    Faiez Zannad, MD, PhD
    Professor
    Université de Lorraine
    Nancy, France 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop a higher index of suspicion for identifying patients at risk for potassium abnormalities.
    • Implement management strategies to normalize potassium disturbances and optimize treatment in patients with heart failure and/or chronic kidney disease who are receiving RAASi therapy.
  • Target Audience

    This activity is designed to meet the educational needs of heart failure specialists, cardiologists, primary care physicians, nephrologists, and all other allied healthcare professionals involved in the diagnosis, treatment, and care of heart failure.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The most common risk factors for hyperkalemia are reduced kidney function and treatment with renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. With evidence showing the increased risk of morbidity and mortality associated with hyperkalemia caused by stopping RAASi therapy, how can we best manage potassium abnormalities and protect our patients through optimized RAASi therapy?

    This panel discussion featuring Drs. George Bakris, Matthew Weir, and Faiez Zannad will highlight the latest tools for treating hyperkalemia as well as practice tips for its continued management while titrating RAASi therapy to the most effective levels. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    George Bakris, MD
    Professor of Medicine
    Director, AHA Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, IL 

    Consulting Fees: Alnylam, Ionis, Merck, Relypsa
    Principal Investigator/Steering Committee: Bayer, Novo Nordisk, Vascular Dynamics 

    Faculty:
    Matthew R. Weir, MD
    Division Head, Nephrology
    University of Maryland
    School of Medicine
    Baltimore, MD 

    Consulting Fees: AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Relypsa, Vifor Pharma

    Faiez Zannad, MD, PhD
    Professor
    Université de Lorraine
    Nancy, France 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop a higher index of suspicion for identifying patients at risk for potassium abnormalities.
    • Implement management strategies to normalize potassium disturbances and optimize treatment in patients with heart failure and/or chronic kidney disease who are receiving RAASi therapy.
  • Target Audience

    This activity is designed to meet the educational needs of heart failure specialists, cardiologists, primary care physicians, nephrologists, and all other allied healthcare professionals involved in the diagnosis, treatment, and care of heart failure.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/22/20